Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.
Nizar J. Bahlis, MD
Advertisement
Articles by Nizar J. Bahlis, MD
Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.
Nizar J. Bahlis, MD, discusses daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 9/20
4
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
5